sheep haemolytic serum (Wellcome Reagents; 3 minimum haemolytic doses in a volume of 0 5 ml) were then added and the samples incubated at 37°C for a further 30 minutes. The samples were then diluted with 1 ml of barbitone buffered saline, pH 7-2, and centrifuged at 3,000 g for 10 minutes. The release of haemoglobin into the supernatant was estimated spectrophotometrically by absorbance at 540 nm, and the percentage inhibition of red cell lysis was calculated from the saline control maximum release.
. With all serum samples studied the anti-complementary activity was localized predominantly in fractions III, IV, and V-that is, in the ascending limb of the 7S peak-while fractions I, II, VI, and VII were inactive. fig. 2 . Fractions I, II, and VII contained less than 15 mg IgG/100 ml whereas fractions III, IV, V, and VI contained substantial amounts of IgG; 62 mg, 160 mg, 230 mg, and 142 mg/100 ml respectively.
Discussion
The results show that anti-complementary activity is present in the serum of a significant proportion of patients with Hashimoto thyroiditis, primary hypothyroidism, or thyrotoxicosis, the greatest frequency being detected in serum from patients with Hashimoto thyroiditis.
The anti-complementary activity of Hashimoto serum was localized predominantly in the ascending region of the second peak and is therefore of molecular size larger than monomeric IgG but smaller than IgM. The fact that substantial amounts of IgG were present in all fractions containing anti-complementary activity and that the distribution of anti-complementary activity was localized only in the early portion of the IgG profile suggests that this property may be due to a small antigenic determinant in combination with IgG. Since the anti-complementary assay gives no indication of the nature of the inhibitory factors involved, there is also the possibility that this activity could be due to aggregated IgG. This would seem to be unlikely since serum samples from both control subjects and thyroid patients were tested within one month of collection and had been frozen and thawed only twice.
Current experiments (Calder et al., 1974) investigating the lymphoid cell dependent cytotoxic effect of Hashimoto serum fractions on thyroglobulin-coated target cells have shown that significant cytotoxicity is localized in both the first and second elution peaks. The observed anti-complementary activity of Hashimoto serum may be due to the presence of thyroglobulinantibody complexes though thyroglobulin antibodies are only weakly complement fixing (Roitt et al., 1958) . Recent investigations by Hay and Torrigiani (1973) suggest that the reason for the poor complement fixation observed in this system is dependent on the nature of the thyroglobulin molecule rather than on the antibodies. Whether in fact thyroglobulin antibody in combination with small fragments of the thyroglobulin molecule is capable of fixing complement as a result of exposure of different antigenic sites is at present unknown. It is possible that the anti-complementary activity of Hashimoto serum is due to complex formation with other antigens, in particular to thyroid microsomal antigen and the complement-fixing thyroid microsomal antibody.
The difference in frequency of anti-complementary activity in the three clinical groups of thyroid disease indicate that circulating immune complexes of the optimum size for binding complement are more common in the serum of patients with Hashimoto thyroiditis. This could reflect variations in the degree and type of tissue damage occurring in these different disease states resulting in the release of thyroglobulin, its subcomponents, or other thyroid antigens.
